The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Support from DFC will help produce one billion vaccine doses by the end of 2022
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In India, almost all approved vaccines are packed in FIOLAX glass made by SCHOTT
Subscribe To Our Newsletter & Stay Updated
